Related Experiment Video
Updated: Aug 26, 2025
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Platelet MicroRNA-484 as a Novel Diagnostic Biomarker for Acute Coronary Syndrome
Parisa Masoodi Khabar1, Mohamad Esmail Ghydari2, Nader Vazifeh Shiran1
1Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Objective:
Platelet microRNAs (miRs) have been indicated as a diagnostic biomarker in various diseases, including acute coronary syndrome (ACS). This study aimed to investigate the expression of miR-223-5p, miR-126-5p, miR-484, and miR-130a-3p in individuals with coronary artery disease (CAD).
Methods:
Forty subjects with CAD and 13 healthy individuals were under study. The expression of miR-223-5p, miR-126-5p, miR-484, and miR-130a-3p was measured in platelets by quantitative reverse transcription-polymerase chain reaction. The relationship between miRNA expression and various parameters of the subjects was analyzed using analysis of variance and Spearman and t-tests.
Results:
The miR-484 expression was significantly upregulated in the ACS subjects (P = .0097). Moreover, miR-484 had diagnostic value for screening subjects with unstable angina vs controls (area under the curve [AUC] = 0.978, 95% confidence interval [CI] 0.92-1, P = .0006) and NSTEMI patients versus controls (AUC = 0.910, 95% CI 0.74-1, P = .005).
Conclusion:
The results of this study indicate that the upregulated expression of miR-484 in ACS patients might be used as a diagnostic biomarker in ACS.
Insights
Platelet microRNA-484 (miR-484) shows increased expression in acute coronary syndrome (ACS) patients. This finding suggests miR-484 can serve as a valuable diagnostic biomarker for detecting ACS.
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Medicine
Background:
- Platelet microRNAs (miRs) are emerging biomarkers for various diseases.
- Acute coronary syndrome (ACS) diagnosis can be improved with novel biomarkers.
Purpose of the Study:
- To investigate the expression levels of miR-223-5p, miR-126-5p, miR-484, and miR-130a-3p in individuals with coronary artery disease (CAD).
- To assess the potential of these miRs as diagnostic biomarkers for ACS.
Main Methods:
- Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to measure miRNA expression in platelets.
- Forty CAD patients and 13 healthy controls were included in the study.
- Statistical analyses included ANOVA, Spearman, and t-tests.
Main Results:
- miR-484 expression was significantly upregulated in ACS patients compared to controls (P=.0097).
- miR-484 demonstrated high diagnostic value for distinguishing unstable angina patients from controls (AUC=0.978, P=.0006).
- miR-484 also showed diagnostic value for differentiating NSTEMI patients from controls (AUC=0.910, P=.005).
Conclusions:
- Upregulated miR-484 expression in ACS patients indicates its potential as a diagnostic biomarker.
- miR-484 could aid in the early and accurate diagnosis of acute coronary syndrome.
More Related Videos
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...